MA56526B1 - Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine - Google Patents

Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Info

Publication number
MA56526B1
MA56526B1 MA56526A MA56526A MA56526B1 MA 56526 B1 MA56526 B1 MA 56526B1 MA 56526 A MA56526 A MA 56526A MA 56526 A MA56526 A MA 56526A MA 56526 B1 MA56526 B1 MA 56526B1
Authority
MA
Morocco
Prior art keywords
immunodeficiency virus
human immunodeficiency
pyrido
inhibitors
virus replication
Prior art date
Application number
MA56526A
Other languages
English (en)
Other versions
MA56526A (fr
Inventor
Eric P Gillis
Christiana Iwuagwu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA56526A publication Critical patent/MA56526A/fr
Publication of MA56526B1 publication Critical patent/MA56526B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé et ses sels pharmaceutiquement acceptables, ainsi que des compositions et des méthodes de traitement d'une infection par le virus de l'immunodéficience humaine (vih).
MA56526A 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine MA56526B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Publications (2)

Publication Number Publication Date
MA56526A MA56526A (fr) 2022-04-27
MA56526B1 true MA56526B1 (fr) 2024-05-31

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56526A MA56526B1 (fr) 2019-06-19 2020-06-17 Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine

Country Status (29)

Country Link
US (1) US20210323967A1 (fr)
EP (1) EP3986561B1 (fr)
JP (1) JP2022537047A (fr)
KR (1) KR20220024608A (fr)
CN (1) CN114245795B (fr)
AR (1) AR119174A1 (fr)
AU (1) AU2020295793B2 (fr)
BR (1) BR112021025655A2 (fr)
CA (1) CA3143136A1 (fr)
CL (1) CL2021003388A1 (fr)
CO (1) CO2021017479A2 (fr)
CR (1) CR20210664A (fr)
DK (1) DK3986561T3 (fr)
ES (1) ES2974541T3 (fr)
FI (1) FI3986561T3 (fr)
HR (1) HRP20240501T1 (fr)
HU (1) HUE065762T2 (fr)
IL (1) IL288750A (fr)
LT (1) LT3986561T (fr)
MA (1) MA56526B1 (fr)
MD (1) MD3986561T2 (fr)
MX (1) MX2021016149A (fr)
PE (1) PE20220510A1 (fr)
PL (1) PL3986561T3 (fr)
PT (1) PT3986561T (fr)
RS (1) RS65304B1 (fr)
SI (1) SI3986561T1 (fr)
UY (1) UY38755A (fr)
WO (1) WO2020254985A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190854A1 (ru) 2018-10-24 2021-08-17 ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД Ингибиторы репликации вируса иммунодефицита человека
WO2021116872A1 (fr) * 2019-12-09 2021-06-17 Viiv Healthcare Company Compositions pharmaceutiques contenant du cabotégravir
AU2021231447A1 (en) * 2020-03-06 2022-09-22 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855A1 (en) 2021-10-13 2024-05-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000149A (es) * 2008-07-02 2011-02-24 Avexa Ltd Compuestos que tienen propiedades antivirales.
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
WO2013006738A1 (fr) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Composés pour traiter le vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
PT2943487T (pt) 2013-01-09 2016-12-15 Gilead Sciences Inc Heteroarilos de 5 membros e sua utilização como agentes antivirais
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (fr) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Composés thérapeutiques pour le traitement d'infections virales
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
NZ729150A (en) 2014-08-29 2018-02-23 Gilead Sciences Inc Antiretroviral agents
PL3597646T3 (pl) * 2016-08-19 2023-12-11 Gilead Sciences, Inc. Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV
ES2826748T3 (es) * 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana

Also Published As

Publication number Publication date
CL2021003388A1 (es) 2022-09-30
CN114245795A (zh) 2022-03-25
LT3986561T (lt) 2024-04-25
EP3986561B1 (fr) 2024-02-14
BR112021025655A2 (pt) 2022-02-01
CN114245795B (zh) 2024-08-06
CR20210664A (es) 2022-01-21
JP2022537047A (ja) 2022-08-23
IL288750A (en) 2022-02-01
HRP20240501T1 (hr) 2024-07-05
AU2020295793A1 (en) 2022-01-20
DK3986561T3 (da) 2024-03-04
RS65304B1 (sr) 2024-04-30
CA3143136A1 (fr) 2020-12-24
UY38755A (es) 2020-11-30
MA56526A (fr) 2022-04-27
PL3986561T3 (pl) 2024-06-10
MD3986561T2 (ro) 2024-06-30
US20210323967A1 (en) 2021-10-21
MX2021016149A (es) 2022-05-18
CO2021017479A2 (es) 2022-04-19
AR119174A1 (es) 2021-12-01
TW202115055A (zh) 2021-04-16
PT3986561T (pt) 2024-03-15
FI3986561T3 (fi) 2024-05-02
WO2020254985A1 (fr) 2020-12-24
EP3986561A1 (fr) 2022-04-27
SI3986561T1 (sl) 2024-04-30
HUE065762T2 (hu) 2024-06-28
KR20220024608A (ko) 2022-03-03
PE20220510A1 (es) 2022-04-07
ES2974541T3 (es) 2024-06-27
AU2020295793B2 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
MA56526B1 (fr) Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
CL2019002204A1 (es) Compuestos inhibidores del vih.
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MX2022002897A (es) Profarmacos antivirales y formulaciones de los mismos.
CA3013473C (fr) Methodes de prevention et de traitement du vih et du sida
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
EA202192433A1 (ru) Соединения, полезные в терапии вич
UY27577A1 (es) Inhibidores de la integrasa del vih
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA43960B1 (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
MX2022011016A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
MA43507B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MX2024006176A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno.
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.